HSPA9 and endometrial cancer: Consistent with the disruptions of mortalin binding to metabolic enzyme client proteins, SHetA2 treatment forced endometrial cancers cells into a quiescent state by inhibiting both oxidative phosphorylation and glycolysis (Chandra et al., 2021).